FierceBiotech Feb 5, 2026 Quell halts liver transplant Treg trial to focus on preclinical 'chill not kill' candidate
FierceBiotech Feb 5, 2026 FDA’s rare pediatric disease voucher program revived by 2026 government funding bill
FierceBiotech Feb 4, 2026 Lilly drops 3 pipeline drugs, including gene therapy, from $1B Prevail buyout
FierceBiotech Feb 4, 2026 Hims & Hers to sell Grail’s Galleri multi-cancer blood test via its digital health platform
FierceBiotech Feb 4, 2026 NHS 'FIT' bowel cancer test reduced unnecessary referrals as cancer numbers remain stable
FierceBiotech Feb 4, 2026 Novo's CEO 'wishes Pfizer luck' with Metsera drug, but still seeks own monthly GLP-1
FierceBiotech Feb 4, 2026 Amgen advances toward lupus redemption while gastric cancer candidate struggles
FierceBiotech Feb 4, 2026 NIH turmoil takes center stage as director acknowledges no vaccine-autism link
FierceBiotech Feb 3, 2026 Pfizer CEO says pipeline pruning is mostly finished after 6 more early-stage culls, $4.4B in impairment charges
FierceBiotech Feb 3, 2026 Fledgling biotech Exxel plans $13M IPO to succeed where other FAAH inhibitors have failed
FierceBiotech Feb 3, 2026 FDA signals tailored approach to ‘carefully shepherd’ CAR-T therapy for autoimmune diseases